Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations

Last updated: March 10, 2026
Sponsor: NYU Langone Health
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Post-traumatic Stress Disorders

Treatment

Treatment as Usual

Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)

Clinical Study ID

NCT06307340
22-01058
  • Ages > 18
  • All Genders

Study Summary

During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • must be 18 years or older,

  • be a patient at the START clinic receiving methadone for treatment of opioid usedisorder,

  • self-report 10+ days of co-use of cocaine and illicit opioids in the past 30-days,

  • meet the criteria for stimulant use disorder (cocaine type; mild, moderate orsevere) and a score of 3≥ on the PC-PTSD-5.

Exclusion

Exclusion Criteria:

  • cognitive impairment that would interfere with their ability to understand studyparticipation as assessed by the researcher,

  • does not speak/understand English at a conversational level,

  • plans to leave the START clinic in the next 60 days,

  • patients who missed methadone doses (inactive) for 30 days or more, or

  • having received clinical care from the interventionist(s) in the past 30 days

Study Design

Total Participants: 76
Treatment Group(s): 2
Primary Treatment: Treatment as Usual
Phase:
Study Start date:
October 14, 2024
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • Florida State University

    Tallahassee, Florida 32306
    United States

    Site Not Available

  • Florida State University

    Tallahassee 4174715, Florida 4155751 32306
    United States

    Site Not Available

  • START Treatment and Recovery Centers

    Brooklyn, New York 11238
    United States

    Site Not Available

  • NYU Langone Health

    New York, New York 10016
    United States

    Site Not Available

  • START Treatment and Recovery Centers

    Brooklyn 5110302, New York 5128638 11238
    United States

    Site Not Available

  • NYU Langone Health

    New York 5128581, New York 5128638 10016
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.